Schizophrenia – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Schizophrenia – Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects
- The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Schizophrenia
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3Z ehfAbbVie Inc
Acadia Pharmaceuticals Inc
Adamed Pharma SA
Adare Pharma Solutions
Addex Therapeutics Ltd
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Ananda Scientific Inc
Anavex Life Sciences Corp
Athira Pharma Inc
Autifony Therapeutics Ltd
Avicanna Inc
BCWorld Pharm Co Ltd
Benuvia Therapeutics Inc
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Bukwang Pharmaceutical Co Ltd
Cellix Bio Pvt Ltd
Celon Pharma SA
Centre for Addiction and Mental Health
Cerevance Inc
Cerevel Therapeutics Holdings Inc
Curemark LLC
CuroNZ Ltd
Daewoong Pharmaceutical Co Ltd
Daya Drug Discoveries Inc
Delpor Inc
Denovo Biopharma LLC
Echo Pharmaceuticals BV
Endosane Pharmaceuticals GmbH
Entheogenix Biosciences Inc
Exavir Therapeutics Inc
Exscientia Plc
Gabather AB
Genochem SAS
GP Pharm SA
Guangzhou Diqi Pharmaceutical Technology Co Ltd
H. Lundbeck AS
Hangzhou Heze Pharmaceutical Technology Co Ltd
Helmholtz Association of German Research Centres
Herophilus
Hyundai Pharma Co Ltd
Intra-Cellular Therapies Inc
Io Therapeutics Inc
Jaguar Health Inc
Jazz Pharmaceuticals Plc
Jiangsu Enhua Pharmaceutical Group Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Johnson & Johnson
Karuna Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
LB Pharmaceuticals Inc
Lead Discovery Center GmbH
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Malachite Innovations Inc
MapLight therapeutics Inc
MedinCell SA
Mental-Heal Ltd
Merck & Co Inc
Minerva Neurosciences Inc
Myrobalan Therapeutics Inc
Nanjing Noratech Pharmaceutical Inc
Nanomi BV
National Institute of Neurological Disorders and Stroke
National Taiwan University
Neonc Technologies Inc
Neumora Therapeutics Inc
Neurelis Inc
Neurocrine Biosciences Inc
NeurOp Inc
NeuroSolis Inc
Newron Pharmaceuticals SpA
Nostrum Biodiscovery SL
Novartis AG
Omeros Corp
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
Ovid Therapeutics Inc
OWP Pharmaceuticals Inc
Pasithea Therapeutics Corp
PharmAla Biotech Inc
ProMIS Neurosciences Inc
Qilu Pharmaceutical Co Ltd
Ra Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shanghai BociMed Pharmaceutical Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shanghai Pharmaceutical Group Co Ltd
Shanghai Zhongze Medicine Tech Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Siragen Pharmaceuticals Inc
SkySea Pharmaceutical Inc
Sosei Group Corp
Spanish National Research Council
Sumitomo Pharma America Inc
Sumitomo Pharma Co Ltd
Suven Life Sciences Ltd
Suzhou Vigonvita Life Sciences Co Ltd
SyneuRx International (Taiwan) Corp
Taho Pharmaceuticals Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
The Greater Cannabis Company Inc
Therapeutic Solutions International Inc
Tisento Therapeutics Inc
University of Maryland
Valentec
Vanda Pharmaceuticals Inc
Vanderbilt University
Verge Genomics
Vivozon Inc
Whan In Pharm Co Ltd
Wisdom Pharmaceutical Co Ltd
YaoPharma Co Ltd
Yoda Pharmaceuticals Inc
Zezheng Shanghai Biotechnology Co Ltd
Zhejiang Jingxin Pharmaceutical Co Ltd